Abstract
Cancer is a major public health burden in both developed and developing countries. Plant-derived compounds have been an important source of several clinically useful anti-cancer agents including taxol, vinblastine, vincristine, the camptothecin derivatives, topotecan and irinotecan, and etoposide derived from epipodophyllotoxin are in clinical use all over the world. About 30 plant derived compounds have been isolated so far and are currently under clinical trials. Cancer chemopreventive agents, many of which are natural products, are capable of preventing or inhibiting the process of carcinogenesis. As with other pharmaceutical agents useful for disease prevention, a pharmacoeconomic analysis of a cancer chemopreventive formulation would need to be considered, and the composition of the formulation should improve over time. A number of promising new agents are in clinical development based on selective activity against cancer-related molecular targets, including flavopiridol, roscovitine, combretastatin A-4 phosphate , betulinic acid and silvestrol are in clinical or preclinical development .
References
G Samuelson . Drugs of natural origin: a textbook of Pharmacognosy. 4th edition, Stockholm, Swedish Pharmaceutical Press, 1999.
GM Cragg; DJ Newmann; KM Snader. Journal of Natural Products, 1997, 60, 52-60.
LD Kappor. CRC Handbook of Ayurvedic medicinal plants. Boca Raton, Florida, CRC Press, 1990, 416-417.
GM Cragg; DJ Newmann. Journal of Ethnopharmacology, 2005, 100, 72-79
T Kutluk; A Kars. General Knowledge about cancer. Ankara; Turkey cancer investigation and fight society publications, 1998, 7-15.
S Turgay; D Sar. Turkistan, Premethod, 2005, 436-441.
R Pinar. To investigate knowledge of Turkish people about cancer. Cancer agenda, 1998, 2, 66-73.
JR Mann; N Dibois. Drug Discovery Today, 2004, 403-409.
JS Bertan. Molecular aspects Medicine, 2001, 21, 167-223.
Estrogen and cancer website, 2006.
BN Ames; LS Gold. The causes and prevention of cancer procedure natl. Academic sciences USA. 1995, 92, 5258-5265.
S Koduru; DS Grierson. Current Science, 2007, 92, 906-908.
American Cancer Society, Facts and Figures, 1999.
S Madhuri. Plant Archives, 2008, 8, 13-16.
S Sivalokanathan; M Ilayara. Indian Journal of Experimental Biology. 2005, 43, 264-67.
GM Crag; DJ Newmann. Journal of Ethnopharmacology, 2005, 100, 72-79.
GJ Creemer; G Bolis; G Scarfome; I Hudson. Topotecan, Journal of Clinical oncology, 1996, 14, 3056-3061.
JR Bertino. Oncology, 1997, 24, S18-S23.
AL Harvey. Trends Pharmaceutical Sciences, 1999, 20, 196-98.
H Itokawa; X Wang. Homoharringtonine and related compounds. In: Cragg GM, Kingston DGI. Newman D (eds) Anticancer agents from natural products. Boca Raton, Florida, Brunner- Routledge Psychology Press, Taylor and Francis Group. 2005, 47-70.
K Ohsumi; R Nakagawa; Y Fukuda; T Hatanaka. Journal of Medicinal Chemistry, 1998, 41, 705-06.
GR Petit; SB Singh; ML Niven; E Hamel. Journal of Natural Products, 1987, 50, 119-20.
RH Cichewitz; SA Kouzi. Medicinal Research Review, 2004, 24, 90-114.
E Pisha; H Chai; IS Less; JM Pezzuto. Natural Medicine, 1995, 1, 1046-51.
GM Cragg; DJ Newmann; S Holbeck. Curent Cancer drug targets, 2002, 2, 279-308.
L Pieters; T Debruyne; M Claeys. Journal of Natural Products, 1993, 56, 899-906.
JL Hartwell. Plants used against cancer; A survey. Lloyadia. 1969, 32, 158-176.
MI Lopes; J Lopes. Journal of Ethnopharmacology, 2004, 95, 437-445.
J Popoca; A Aguilar; D Alonso. Journal of Ethnopharmacology, 1998, 59,173-77.
T Howiriny; M Sohaibani. Journal of Ethnopharmacology, 2005, 98, 287-94.
A Calis; D Yuruker; AD Tasdemir. Planta Medica, 1997, 63, 183-86.
J Liu; H Shen. Cancer Letters, 2000, 153, 85-93.
B Fernanda; J Daniela. Toxicon, 2005, 45, 459-66.
S Lee; KT Lim. Journal of Food Sciences, 2003, 68, 466-470.
HALL T. C. : Chemotherapy of cancer.. New Eng. J. Med.. 266:289,1962;.
FROST J. W., GOLDWEIN M. I., BRYAN J. A. : Clinical experience with vincaleukoblastine in far-advanced Hodgkin's disease and various malignant states.. Ann. Intern. Med.. 58:584,1962;.
MIDWEST COOPERATIVE CHEMOTHERAPY GROUP, : Vinblastine in neoplastic disease.. Cancer Res.. 23:169,1963;.
HODES M. E., ROHN R. J., BOND W. H., YARDLEY J. M., CARPENING W. S. : Vincaleukoblastine. IV. A summary of two and one-half years' experience in use of vinblastine.. Cancer Chemother. Rep.. 16:401,1962;.
KARNOFSKY D. A. : Meaningful clinical classification of therapeutic responses to anti-cancer drugs. (editorial).Clin. Pharmacol. Ther.. 2:709,1961;.
AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985;253:1590-1591.
National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia. 1983;1:426-428.
M. C. Wani, D. M. Brown, M. J. O'Neill, J. A. Lewis, J. M. Besterman. In New Trends in Natural Product Chemistry (Atta-ur-Rahman, M. I. Choudhary, eds), pp. 79±94. Harwood Academic Publishers, Amsterdam (1998).
A. Artuso. Drugs of Natural Origin. Economic and Policy Aspects of Discovery, Development, and Marketing, pp. 3±4. The Pharmaceutical Products Press. Binghampton, New York (1997).
Anonymous. Taxotere.com for Healthcare Professionals: Pharmacokinetics. Sanofi-aventis U.S. LLC.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array